SOUTH SAN FRANCISCO, Calif.
April 1, 2013
/PRNewswire/ -- KaloBios Pharmaceuticals (Nasdaq: KBIO) today announced that the company has been selected to present at the 2013 BioCentury-Thomson Reuters Future Leaders in the Biotech Industry Conference, to be held in New York City on
April 5, 2013
. KaloBios President and Chief Executive Officer,
David W. Pritchard
, will provide an overview of KaloBios and the company's three current clinical programs for its proprietary, patient-targeted monoclonal antibody therapeutics.
Friday, April 5, 2013
9:00 am EDT
, Presentation Room 311Where: Millennium Broadway Hotel and Conference Center,
New York, NY
To access the live and archived audio webcast of the KaloBios Future Leaders presentation please log on through a link located in the Investors section of the KaloBios Pharmaceuticals website under the Events & Presentations tab:
A replay of the webcast will be available one hour after the conclusion of the live event.
KaloBios Pharmaceuticals, Inc. is developing a portfolio of patient-targeted, first-in-class monoclonal antibodies to treat serious medical conditions with a primary clinical focus on respiratory diseases and cancer. For more information on KaloBios Pharmaceuticals, please visit our web site at
Jeffrey H. Cooper
Chief Financial OfficerKaloBios Pharmaceuticals, Inc.(650) 243-3146
Joan E. Kureczka
Kureczka/Martin Associates Tel: (415) 821-2413Mobile: (415) 690-0210
SOURCE KaloBios Pharmaceuticals, Inc.